EN DE
Watch IMB Dx, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

IMB Dx, Inc (461030) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of IMB Dx, Inc stock KRW 1,509, price KRW 2,310, that is 34.7% below the price, quality 42 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

ID IMB Dx, Inc logo Thin data Nov 3, 2026

IMB Dx, Inc

461030 · KQ
Expensive, weak quality

Our calculation puts a fair price 35% below what the stock costs today.

Quality 42/100
Expensive Growth (revenue 3y +26.6 %/yr in KRW)
Fair value 1,509 KRW · Overvalued
Loss-making · -135.5% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 12/100
Thin data
Watch IMB Dx, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

36,000 KRW 2,310 KRW Fair Value 1,509 KRW Apr 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

31‑month range 2,310 KRW – 36,000 KRW · fair‑value band 996.12 KRW – 1,887 KRW · the 2,310 KRW price screens above the 1,509 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow IMB Dx in your weekly email

Every Wednesday you see whether IMB Dx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IMB Dx, Inc. provides liquid biopsy platform in South Korea.

Show moreShow less

It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test.

The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.

Stock analysis

IMB Dx, Inc (461030) currently trades at 2,310 KRW, while our model-based Fair Value estimate is 1,509 KRW, 35% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 996.12 KRW (bear) to 1,887 KRW (bull), the price of 2,310 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

IMB Dx, Inc reported revenue of 5.3B KRW in FY2025 versus 1.2B KRW in FY2021, a compound +44.3%/yr. Reported net income was −7.9B KRW in FY2025.

Key figures

Market cap 32.4B KRW (≈ $23.9M) Micro · P/S ratio 6.18 · EPS (TTM) −529.39 KRW · Net margin −136% · Return on equity −29.0% · Return on assets (EBIT) −42.8% (5-year average) · Operating margin −93.2% · Revenue (TTM) 5.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −35%, 461030 screens richer than that median.

Fair Value models

Bear 996.12 KRW Fair Value 1,509 KRW Bull 1,887 KRW
Price 2,310 KRW · Downside -34.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 996.12 KRW 1,509 KRW 1,887 KRW 52
All 1 models by family
Asset-Based
NCAV (Graham) 996.12 KRW 1,509 KRW 1,887 KRW 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 13
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+56.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−429.0% (2021) → −162.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

461030 screens overvalued: fair value 35% below the price. Compare with Thermo Fisher Scientific Inc →

Compare IMB Dx, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 125 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −34.7% · Below median
Profitability
Return on assets −29.3% · Bottom 25%
Net margin (12 months) −135.5% · Bottom 25%
Operating margin (12 months) −93.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.29× · Cheaper than median
P/S (12 months) 5.78× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
IQVIA Holdings IQV $271.83 $299.01 +10% vs 461030
Illumina, Inc ILMN $213.13 $234.44 +10% vs 461030
WuXi AppTec Co 603259 ¥150.29 ¥164.66 +10% vs 461030
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 461030
Danaher Corporation DHR $230.25 $209.18 −9% vs 461030
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 461030
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 461030
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 461030
Lonza Group LONN CHF 659.40 CHF 153.50 −77% vs 461030
Waters Corporation WAT $457.60 $91.26 −80% vs 461030

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IMB Dx, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "IMB Dx, Inc Fair Value". https://www.fairvalue-calculator.com/stock/461030

Frequently asked questions

Is IMB Dx, Inc (461030) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 1,509 KRW versus a price of 2,310 KRW, about 35% lower (overvalued).
What is the fair value of 461030?
Our model-based fair value for IMB Dx, Inc is 1,509 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,310 KRW.
What is the quality score of 461030?
IMB Dx, Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IMB Dx, Inc (461030)?
Our model-based price target is the fair value of 1,509 KRW (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 996.12 KRW, optimistic scenario 1,887 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the IMB Dx, Inc stock forecast for 2026?
Our models put fair value at 1,509 KRW, about 35% lower versus a price of 2,310 KRW (overvalued). Cautious scenario 996.12 KRW, optimistic scenario 1,887 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of IMB Dx, Inc (461030)?
IMB Dx, Inc reported trailing-twelve-month revenue of about 5.6B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of IMB Dx, Inc (461030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IMB Dx, Inc it is 1,509 KRW per share (as of Nov 3, 2026), against a price of 2,310 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is IMB Dx, Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 461030 trades above its calculated fair value: price 2,310 KRW, fair value 1,509 KRW, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 461030?
No. The price is what the market pays today (2,310 KRW); the fair value is what the company's own numbers justify (1,509 KRW). For IMB Dx, Inc the two are 800.72 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is IMB Dx, Inc worth?
The market values IMB Dx, Inc at about 32.4B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,310 KRW; our models calculate a fair value of 1,509 KRW per share.
What do the bullish and bearish scenarios say about 461030?
Our models span a range for IMB Dx, Inc: cautious scenario 996.12 KRW, base 1,509 KRW, optimistic 1,887 KRW per share (as of Nov 3, 2026, price 2,310 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IMB Dx, Inc (461030)?
Balance-sheet figures for IMB Dx, Inc (as of Nov 3, 2026): return on equity −29.0%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 461030 from its 52-week high?
IMB Dx, Inc trades at 2,310 KRW, about 81% below its 52-week high of 12,080 KRW and at the low of 2,310 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1,509 KRW is for.
Which stocks are comparable to IMB Dx, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IMB Dx, Inc stock attractive at the current price?
The data as of Nov 3, 2026: price 2,310 KRW, calculated fair value 1,509 KRW (−35%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 461030 calculated?
We run IMB Dx, Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,509 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. IMB Dx, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IMB Dx, Inc (461030)?
The closing price on Nov 9, 2026 was 2,310 KRW. Our model-based fair value is 1,509 KRW, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IMB Dx, Inc right now?
The price sits above even our optimistic bull case (1,887 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (996.12 KRW to 1,887 KRW) leaves room in how you read the outcome.

Key figures of IMB Dx, Inc

How large is the market capitalisation of IMB Dx, Inc (461030)?
The market capitalisation of IMB Dx, Inc is 32.4B KRW (≈ $23.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IMB Dx, Inc (461030)?
The price-to-sales ratio of IMB Dx, Inc is 6.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IMB Dx, Inc (461030)?
Earnings per share at IMB Dx, Inc are −529.39 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IMB Dx, Inc (461030)?
The net margin of IMB Dx, Inc is −136% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IMB Dx, Inc (461030)?
The return on equity (ROE) of IMB Dx, Inc is −29.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IMB Dx, Inc (461030)?
On an EBIT basis the return on assets of IMB Dx, Inc is −42.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IMB Dx, Inc (461030)?
The operating margin of IMB Dx, Inc is −93.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does IMB Dx, Inc (461030) generate?
The free cash flow of IMB Dx, Inc is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch IMB Dx, Inc in the live analysis

One click puts IMB Dx, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.